Kelun-Biotech and Merck’s Antibody Drug Conjugate Demonstrates Superiority Over Keytruda in Pivotal Lung Cancer Trial
Chinese biopharma company Kelun-Biotech announced on Thursday a significant advancement in oncology, revealing that an investigational antibody drug conjugate (ADC) developed in collaboration with Merck (MRK) demonstrated superior efficacy compared…
